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Abstract
Evidence from epidemiological studies suggests that
plant-based diets can reduce the risk of prostate cancer.
However, very little information is available concerning
the use of botanicals in preventing prostate cancer.
As a first step toward developing botanicals as prostate
cancer preventives, we examined the effect of Nexrutine
on human prostate cancer cells. Nexrutine is a herbal
extract developed from Phellodendron amurense.
Phellodendron extracts have been used traditionally in
Chinese medicine for hundreds of years as an anti-
diarrheal, astringent, and anti-inflammatory agent. The
present study investigated its potential antitumor effect
onhumanprostate cancer cells. Our results suggest that
it inhibits tumor cell proliferation through apoptosis
induction and inhibition of cell survival signaling. The
results of the present study indicate that Nexrutine
treatment 1) inhibits the proliferation of both androgen-
responsive and androgen-independent human prostate
cancer cells through induction of apoptosis; 2) reduces
levels of pAkt, phosphorylated cAMP response–binding
protein (pCREB), andCREBDNA-binding activity; and 3)
induces apoptosis in prostate cancer cells stably over-
expressing Bcl-2. Further Akt kinase activity was
reduced in cells treated with Nexrutine, and ectopic
expression of myristoylated Akt protected from Nex-
rutine induced inhibition of proliferation, implicating a
role for Akt signaling.
Neoplasia (2006) 8, 523–533
Keywords: Akt/CREB signaling, Bcl-2 – independent apoptosis, Herbal
extracts, Nexrutine, CREB DNA binding.
Introduction
Prostate cancer (PCA) is the most common malignancy
in men especially in the Western world. Approximately
230,000 men are diagnosed with PCA every year in the
United States alone and 30,000 of them die [1]. Although
genetic and epigenetic factors play a major role in the
development and progression of PCA, both experimental
and epidemiological studies show that several agents found
in the human diet may prevent the effects of carcinogenic
agents or suppress the promotional activity in already initi-
ated neoplastic prostatic cells. Even though PCA is the second
leading cause of cancer-related deaths in men, it has a long
latency period that provides opportunities for intervention with
strategies including the use of dietary phytochemicals. Such
strategies may delay disease initiation or progression or will
prevent the development of clinically significant disease. It is
interesting that incidence of PCA is low in the population con-
suming phytochemicals, which are chemical compounds de-
rived from plants such as fruits and vegetables. For example,
genistein, the most abundant phytochemical component of
soy; resveratrol, found in grapes and peanuts; curcumin, a di-
etary spice; and green tea polyphenols have been implicated
in the prevention of PCA [2–7]. Therefore, the use of dietary
supplements including nutritional and natural products is gain-
ing ground in modulating the risk of development and/or for
treating PCA [7,8]. Estimates also show approximately 40% of
Americans use alternative remedies including herbal medicine
for disease prevention and therapy [7–9]. Such herbal-based
dietary supplements contain a large array of phytochemicals
with polyphenolic constituents (flavonoids) that may mediate
physiological functions related to cancer suppression. An ex-
tract of eight Chinese herbs called PC-SPES has been shown
to inhibit the growth of PCA cells through various mechanisms
involving modulation of apoptosis, androgen receptor expres-
sion, and microtubule synthesis. Evaluation of PC-SPES also
showed a significant response in patients with PCAwith accept-
able toxicity profile. However, it has been recalled by the US
Food and Drug administration because of contamination with
the synthetic estrogen DES, anticoagulant warfarin, and the
anti-inflammatory indomethacin (reviewed in Refs. 7, 8; 10, 11).
Consumption of tomato powder rather than lycopene (an
active tomato ingredient) inhibits prostate carcinogenesis, sug-
gesting that compounds present in the tomato powder in addi-
tion to lycopene modify prostate carcinogenesis [12]. These
data suggest that botanicals and whole foods may work better
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than the single biologically active component. Nexrutine is
a fractionated extract of the traditional Chinese medicine
Phellodendron amurense. Phellodendron extracts have been
used traditionally inChinesemedicine for hundreds of years as
an antidiarrheal, astringent, and anti-inflammatory agent
[13,14]. However, it is not known whether Nexrutine could
be developed as a dietary supplement for prevention or treat-
ment of PCA. In this study we examined the effect of Nex-
rutine on PCA cells and showed that it has a potential to be
developed as an agent for PCA therapy.
Materials and Methods
Preparation of Nexrutine
Nexrutine was provided by Next Pharmaceuticals (Irvine,
CA). Stock solution of Nexrutine was prepared by dissolving
10 mg of Nexrutine in 10 ml DMSO to obtain a concentration
of 1 mg/ml. This was diluted in growth medium to obtain
concentrations of 1 to 10 mg/ml.
Prostate Cancer Cell Lines
Human PCA cell lines, androgen-responsive LNCaP, and
androgen-independent PC-3 cells were grown andmaintained
as described earlier [15–17]. PC-3 Neo and PC-3 Bcl-2 cells
were grown in the presence of 400 mg/ml G 418 [18].
Cell Proliferation Assays
Cancer cells were plated in 96-well plates at a density
of 4000 cells per well in triplicate. After attachment (after
24 hours), cells were treated with different concentrations of
Nexrutine (0.5, 1, 2.5, 5, and 10 mg/ml). Control cells received
only the solvent (DMSO). Cell proliferation was detected
after 72 hours of incubation with Nexrutine by using CellTiter
96 Aqueous One (Promega Corporation, Madison, WI) solu-
tion assay as described by themanufacturer [15,16]. Cell cycle
analysis was performed as described in Kumar et al. [15,16].
Colony Formation Assay
Logarithmically growing LNCaP or PC-3 cells were plated
at a density of 13,000 cells/ml in 0.5% agarose plates in
triplicate without and with increasing concentrations of Nex-
rutine (2.5, 5, 7.5, and 10 mg/ml). Plates were prepared fresh
by adding 0.5 g agar (FMC 50102) to 100 ml of complete
growth medium. After incubation at 44jC, 2 ml of this
agarose was evenly layered in six-well plates and allowed
to solidify for 30 minutes. Then 2 ml complete medium con-
taining 0.5% agar was added to 40,000 cells. After mixing,
1 ml medium containing cells was poured on top of the
0.5% medium in the six-well plate. A plate containing no
cells was used as a negative control. After 14 days, cells
were stained with 0.02% p-iodonitrotetrazolium. After
5 hours, the colonies that stained dark pink were counted
in 10 different fields from each well as described earlier [19].
Detection of Apoptosis
LNCaP, PC-3, PC-3 Neo, or PC-3 Bcl-2 cells were plated
at a density of 1  105 in 60-mm dishes. At 70% to 80% con-
fluency, cells were treated with different concentrations of
Nexrutine. After incubation, both adherent and floating cells
were collected by trypsinization for detection of apoptosis by
morphologic analysis; TUNEL assay and 4V-6-diamidino-2-
phenylindole (DAPI) staining. DAPI staining can be used to
distinguish live from apoptotic cells based on the mor-
phology of their nuclei. DAPI forms fluorescent complexes
with double-stranded DNA, and DAPI-stained nuclei show a
bright blue fluorescence when observed under a fluorescent
microscope with DAPI filter.
Preparation of Cell Extracts and Western Blotting
Cells were treated with Nexrutine (5 mg/ml for 24 hours or
at different concentrations and time points as indicated in
the figures) and subsequently lysed in a buffer containing
[50 mM Tris-HCl (pH 7.4), 150 mMNaCl, 0.5% NP40, 50 mM
NaF, 1 mM NaVO4, 1 mM phenylmethylsufonyl fluoride,
25 mg/ml leupeptin, 25 mg/ml aprotinin, 25 mg/ml pepstatin,
and 1 mM DTT]. After the lysate was passed through a
25G needle, cell debris was removed by centrifugation at
12,000 rpm for 30 minutes. Nuclear extracts were prepared
according to the method of Dignam, and protein content of
the extracts was determined by the method of Bradford as
described earlier [15,16].
Equal amounts of extracts were fractionated on a 10%
sodium dodecyl sulfate (SDS)-polyacrylamide gel. After
electrophoresis, proteins were electrophoretically trans-
ferred to a nitrocellulose membrane. The blotted membrane
was blocked with 5% nonfat dry milk in TBS containing 0.1%
Tween 20 (blocking solution), and incubated with indicated
polyclonal antibodies (Santa Cruz Biotechnology, Santa
Cruz, CA; Cell Signaling Technology, Inc., Beverly, MA;
and Upstate Cell Signaling Solutions, Lake Placid, NY) fol-
lowed by incubation with HRP-conjugated anti–rabbit IgG
antibody (Sigma, St. Louis, MO) in blocking solution. Bound
antibody was detected by enhanced chemiluminescence
using Supersignal West Pico Chemiluminescent Substrate,
following the manufacturer’s directions (Pierce, Rockford,
IL). All the blots were stripped and reprobed with b-actin to
ensure equal loading of protein. Each experiment was re-
peated thrice using different sets of extracts.
Preparation of RNA
LNCaP cells at 70% to 80% confluency were treated with
5 mg/ml of Nexrutine for 24 hours. Total RNAwas isolated with
the TRIZOL reagent (Ambion, Austin, TX) according to the
manufacturer’s recommendations as described earlier [20].
Fast Activated Cell-Based ELISA for Akt
We measured the levels and activity of Akt by multiple
approaches including Western blotting, Fast Activated Cell-
Based ELISA (FACE), and immunocytochemistry. We
monitored the phosphorylation of Akt using a more sensitive
kit that specifically measures activated Akt and/or total Akt
quantitatively (Active Motif, Carlsbad, CA). Briefly, cells in
96-well plates were treated with different concentrations of
Nexrutine for 6 hours. After treatment, cells were rapidly
fixed and incubated with a primary antibody that recognizes
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either phosphorylated or total Akt. This was followed by
incubation with secondary HRP-conjugated antibody fol-
lowed by colorimetric development. The relative number of
cells in each well was determined using crystal violet reagent
for normalization.
Transient Expression Assays
Transient transfections were performed in LNCaP cells by
using a lipofectin reagent (Invitrogen, Carlsbad, CA) accord-
ing to the manufacturer’s recommendations. Cells were
transfected with myristoylated Akt or vector alone (pcDNA3)
plasmid (1 mg per well) and incubated for 48 hours. Forty-
eight hours after transfection, cells were treated with Nexru-
tine for 24 hours. After treatment, cells were trypsinized, and
trypan exclusion method was used to determine cell viability
as described earlier [16].
cAMP Response Element Binding Protein
DNA-Binding Activity
cAMP response element binding protein (CREB) DNA-
binding activity was measured in LNCaP and PC-3 nuclear
extracts using TransAM CREB (Active Motif). The sequence
of the wild-type CREB was 5V-AGAGATTGCCTGACGTCA-
AGAGAGCTAG-3V (mutated nucleotides are shown in bold).
Nuclear extracts were prepared from cells treated with Nex-
rutine (5 mg/ml) for different periods (0, 3, 6, 12, and 24 hours).
Briefly, the control and Nexrutine-treated nuclear extracts
were incubated with CREB consensus oligonucleotide that
was immobilized in a 96-well plate. A primary antibody spe-
cific for an epitope on the bound and active form of the CREB
was added followed by subsequent incubation with second-
ary antibody and developing solution. After this incubation,
CREB activity was measured colorimetrically at 450 nm. Nu-
clear extracts prepared from human fibroblast WI-38 cells
stimulated with forskolin (CREB activator) was used as
positive control. For competition experiments, the wells con-
taining immobilized oligo were preincubated with 100-fold
molar excess of wild-type and mutant oligonucleotide for
30 min before addition of the nuclear extract.
Immunocytochemistry
Slides with fixed cells (as described earlier) treated or
untreated with Nexrutine were used. The slides were
washed with TBS and 0.2% Triton X-100, followed by incuba-
tion with a blocking buffer containing 5.5% horse serum in 1
phosphate-buffered saline (PBS) for 1 hour at room temper-
ature. After another washwith TBS, the slideswere incubated
with the primary antibody (pAkt), diluted in blocking buffer
(based on the manufacture’s recommendations) overnight at
4jC with gentle rocking. After three washes with TBS/Triton,
the slides were incubated with a Universal Secondary (Invi-
trogen Corporation, Carlsbad, CA) antibody for 1 hour at
room temperature. After washes with TBS and TBS/Triton,
the slides were incubated with 0.6% hydrogen peroxide for
30 minutes. The slides were washed once more with TBS
and TBS/Triton and stable DAB was added to each spot on
the slide for 15 to 20 minutes. Slides were then rinsed with
water and mounted with a coverslip. Pictures of cells were
taken at 20 and 40 magnification.
Statistical Analysis
Data were presented as average ± S.D. and significance
was determined by using Student’s t test. Differences be-
tween the experimental groups were considered significant
at P < .05.
Results
We examined the effect of Nexrutine on proliferation of
androgen-responsive LNCaP and androgen-independent
PC-3 human PCA cells using the CellTiter 96 Aqueous
One solution assay as described earlier [15,16]. Exponen-
tially growing cells were treated with 0, 1, 2.5, 5, 10, and
25 mg/ml Nexrutine and cell proliferation was measured after
72 hours as described in Materials and Methods. As shown
in Figure 1A, 5 mg/ml of Nexrutine was necessary to inhibit
the growth of LNCaP cells by about 50%; more than 10 mg/ml
was necessary for a similar effect in PC-3 cells. These re-
sults were also confirmed by measuring cell viability using
the trypan blue exclusion method (data not shown). Because
a characteristic feature of transformed cells is their ability
to grow in an anchorage-independent fashion [21], we tested
the effect of increasing concentrations of Nexrutine on
growth of colonies in soft agar. We found that the number
of colonies formed with Nexrutine treatment decreased
with the concentration of Nexrutine (Figure 1B), which was
consistent with the above cell-proliferation data. These data
collectively indicate that Nexrutine inhibits the anchorage-
dependent and -independent growth of PCA cells.
We examined if exposure to Nexrutine may activate
apoptotic pathway in these cells. Cells treated with Nexrutine
were examined for apoptotic features by using a combination
of methods including 1) light microscopy to detect morpho-
logic changes associated with the induction of apoptosis
and 2) TUNEL assay. Exponentially growing LNCaP cells
at 70% to 80% confluence were treated with either solvent
control or different concentrations of Nexrutine (0, 1, 2.5,
and 5 mg/ml for 24 hours). The cells were observed micro-
scopically for treatment-associated morphologic changes.
Significant changes in the morphology of the cells indicative
of apoptosis including rounding of cells with granular appear-
ance were evident after treatment with Nexrutine at a con-
centration of as low as 1 mg/ml. This resulted in detachment
of cells from culture dishes and a significant proportion of
the cells started to float by 24 hours (Figure 2A). Under iden-
tical conditions, the vehicle did not induce any features of
apoptosis. The TUNEL assay used here was a colorimetric
assay that involves incorporation of a biotinylated deoxyuri-
dine 5-triphosphate (dUTP) into 3V-hydroxyl groups that were
generated due to cleavage of apoptotic DNA. Incorporation
of dUTP is detected using streptavidin-HRP conjugate and
the chromogen (diaminobenzidine) is detected as a dark
brown precipitate. As shown in Figure 2B, the nuclei of
Nexrutine-treated cells showed characteristic brown staining
indicative of DNA fragmentation. These data demonstrate
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that Nexrutine induces apoptosis of both LNCaP and PC-3
cells. We also examined the effect of Nexrutine on cell cycle
distribution by measuring cellular DNA content in pro-
pidium iodide–stained cells by flow cytometry. As shown in
Figure 2C, incubation of LNCaP or PC-3 cells with 5 mg/ml of
Nexrutine for 24 hours showed a moderate G1-checkpoint
block. Time course studies are being conducted to deter-
mine whether the observed G1-checkpoint block is respon-
sible for apoptosis induction.
Apoptosis is a complex program involving participation
of several different genes as well as deregulation of cell sur-
vival signaling pathways [22,23]. The Bcl-2 family containing
both proapoptotic and antiapoptotic members has been
shown to play a critical role in the induction of apoptosis in
various systems including prostate [24,25]. To investigate
the mechanistic basis of Nexrutine-induced apoptosis in
LNCaP cells, we examined the levels of Bcl-2 and Bax by
quantitative reverse transcription-polymerase chain reaction
(RT-PCR) and Western blot analysis. Glyceraldehyde-3-
phosphate dehydrogenase (GAPDH) was used as an inter-
nal control for RT-PCR and b-actin for Western blot analysis.
Results presented in Figure 3A show the amplification prod-
ucts of the Bcl-2 and Bax along with GAPDH (bottom band ).
As shown here, there was no significant difference in the
total levels of Bcl-2 after normalization to GAPDH. However,
RNA from Nexrutine-treated samples showed increased
levels of Bax (after normalization to GAPDH) in three dif-
ferent experiments. As shown in Figure 3B, the ratio of Bcl-2/
Bax decreases in a time-dependent fashion in response to
Nexrutine. Apoptosis is regulated by relative ratio of anti-
apoptotic (Bcl-2) and proapoptotic (Bax) family members.
Increased ratio of Bcl-2/Bax favors the formation of anti-
apoptotic heterodimerization of Bcl-2/Bax and homodimeri-
zation between Bcl-2/Bcl-2 leading to inhibition of apoptosis.
However, decrease in the ratio of Bcl-2/Bax favors the for-
mation of Bax/Bax homodimerization leading to induction of
apoptosis. It is possible that the observed decrease in the
ratio of Bcl-2/Bax in response to Nexrutine may favor the
formation of Bax/Bax homodimers with consequent induction
of apoptosis. Similar results were also observed in the pro-
tein level as determined byWestern blot analysis (Figure 3C).
These data indicate that Bcl-2 may not participate directly
in Nexrutine-induced apoptosis in these cells. This also
suggests a possibility that Nexrutine may be useful in inhibit-
ing the growth of tumor cells overexpressing Bcl-2.
To study the role of Bcl-2 in Nexrutine-induced apoptosis
we used PC-3 cell line that is engineered to overexpress Bcl-
2 protein (PC3Bcl-2) and a control cell line that expresses
Bcl-2 at low levels (PC-2Neo [18]). Such high levels of Bcl-2
expression may be similar to those in human tumors. After
examining the levels of Bcl-2 in these cell lines, we evalu-
ated the functionality of the Bcl-2 transgene by testing the
sensitivity of these clones to etoposide treatment. Consistent
with the published data, etoposide inhibited the growth of
PC-3Neo cells, but high levels of Bcl-2 in PC-3 Bcl-2 clones
provided partial protection from etoposide-induced growth
Figure 1. Nexrutine inhibits anchorage-dependent (A) and anchorage-independent (B) growth of human PCA cells. Androgen-responsive (LNCaP) and androgen-
independent (PC-3) cells were plated in 96-well plates as described in Materials and Methods and treated with indicated concentrations of either Nexrutine
(in micrograms per milliliter) or solvent control. Cell proliferation was determined using Cell Titer96 Aqueous One solution assay at 72 hours. Absorbance at 570 nm
determined by using a SpectraMaxPlus plate reader (Molecular Devices, Sunnyvale, CA) is shown. The data shown are averages ± S.D. of three replicate wells
and is representative of four independent experiments. (B) Anchorage-independent growth cells were plated in triplicate in 35-mm dishes on 0.5% agarose
containing medium as described in Materials and Methods. After 14 days’ incubation, cells were stained with 0.5 ml of 0.02% p-iodonitrotetrazolium and colonies
were counted in 10 different fields from each plate. The results are expressed as means ± S.D. and are representative of two independent experiments.
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inhibition (data not shown). Then we tested the effect of
Nexrutine on the proliferation and apoptosis of PC-3 Bcl-2
and PC-3 Neo cells. As shown in Figure 3D, Nexrutine
inhibited the proliferation of PC-3-Bcl-2 cell lines significantly
(P < .034 and < .001 with 5 and 10 mg/ml Nexrutine, re-
spectively, between control versus treated). We used DAPI
staining to determine its effect on apoptosis in these cells.
As shown in Figure 3E, untreated PC-3Neo or PC-3 Bcl-2
cells showed bright homogeneous fluorescence staining
indicating viable cells. However, PC-3 Neo cells treated with
Figure 2. Nexrutine treatment – induced apoptosis. (A) Morphological alterations; (B) apoptosis determined by TUNEL staining. LNCaP and PC-3 cells were
treated with either DMSO or Nexrutine (0, 1, 2.5, and 5 g/ml) for 24 hours. (A) Photomicrographs of cells by phase-contrast microscopy using a Nikon Microscope
with a digital camera system Coolpix 995 (Nikon Corporation, Tokyo, Japan). Original magnification 20. (B) TUNEL staining of LNCaP and PC-3 cells treated with
5 g/ml Nexrutine for 24 hours. Brown-stained nuclei are indicative of apoptosis. (C) Effect of Nexrutine for 24 hours on cell cycle distribution. The data shown are
averages ± S.D. of two independent experiments.
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Nexrutine showed morphologic features indicative of apop-
tosis. PC-3 Bcl-2 cells underwent apoptosis to a lesser ex-
tent in response to Nexrutine treatment. When PC-3 Neo
and PC-3 Bcl-2 cells treated with etoposide (positive control)
were used in DAPI staining, we found apoptotic features only
in PC-3 Neo cells and bright homogenous fluorescence
in PC-3 Bcl-2 cells, indicating that overexpression of Bcl-2
was protecting from etoposide-induced apoptosis (data not
shown). These data indicate Nexrutine-induced apoptosis is
not protected by overexpression of Bcl-2, suggesting it may
not be a direct target.
Because Nexrutine induced apoptosis in the presence of
Bcl-2 we hypothesized that the mechanistic basis of the ob-
served phenomenon could be through modulation of cell
survival signaling pathways. Akt is an antiapoptotic serine-
threonine kinase that regulates a number of critical cellular
Figure 3. Bcl-2 may not be a direct target of Nexrutine-induced biologic effects. (A). Expression of Bcl-2 and Bax was examined using quantitative RT-PCR and
Western blotting. Total RNA and whole-cell protein extracts were prepared from LNCaP cells treated with Nexrutine (5 g/ml for different time intervals). RNA was
used in quantitative RT-PCR with Bcl-2/GAPDH or Bax/GAPDH primers. A representative gel is shown. The bottom band in each lane is GAPDH. (B). Levels of
Bcl-2, Bax, and GAPDH were quantified with KODAK MI software using KODAK Image Station 4000R digital imaging system (Eastman Kodak Company, Kodak
Imaging Systems, New Haven, CT). The ratio of Bcl-2/Bax expression was determined after normalization with GAPDH internal control and shown as a graph.
(C) Equal amounts of the extracts were fractionated on a 10% SDS-polyacrylamide gel and transferred onto a nitrocellulose membrane. The blotted membrane was
blocked with 5% nonfat dry milk in TBS containing 0.1% Tween 20 (blocking solution), and incubated with indicated antibodies followed by incubation with HRP-
conjugated anti – rabbit IgG antibody (Sigma) in blocking solution. Bound antibody was detected by enhanced chemiluminescence using Supersignal West Pico
Chemiluminescent Substrate following the manufacturer’s directions (Pierce, Rockford, IL). The blot shown is a representative blot of three different experiments.
All the blots were stripped and reprobed with -actin to ensure equal protein loading. (D) PC3-Neo (Neo) and PC-3 Bcl-2 (Bcl-2) cells were used in proliferation
assay. Cells were plated in 96-well plates as described in Figure 1A and treated with indicated concentrations of either Nexrutine or solvent control. Cell
proliferation was measured by Cell Titer96 Aqueous One solution assay at 72-hour time point by determining the absorbance at 570 nm using SpectraMaxPlus
plate reader (Molecular Devices). Statistical significance of the data was determined by Student’s t test. (E) PC-3 Neo and PC-3 Bcl-2 cells treated with Nexrutine
(5 g/ml for 24 hours) were trypsinized and used in DAPI staining as described in Materials and Methods. Bright fluorescence indicates viable cells.
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pathways including those leading to cellular proliferation and
inhibition of apoptosis [26–30]. Akt is activated in response
to diverse stimuli by recruitment to the cell membrane
through the actions of phosphotidylinositol 3 kinase (PI3K),
which in turn is regulated by the phosphatase and tensin
homologue deleted from chromosome ten (PTEN). Muta-
tions of PTEN are most commonly encountered in human
cancers including prostate cancer [31]. After activation by
PI3K, Akt translocates to the nucleus where it is thought to
regulate various biologic processes including cell survival
through downstream targets such as GSK, mTOR, caspase
9, and Bad and transcription factors such as forkhead
transcription factor (FKHR), nuclear factor nB (NFnB), and
CREB; [32,33]). To investigate if Nexrutine acts through
such a mechanism, we measured the expression of Akt
and pAkt immunocytochemically. To validate staining, we
used paraffin-embedded LNCaP cell pellets that are either
untreated or treated with LY294002, a PI3K inhibitor. Control
LNCaP cells showed positive staining for pAkt that was
reduced after treatment with LY294002 (data not shown)
and in response to Nexrutine treatment (Figure 4A). We also
performed Western blot analysis with extracts prepared from
PC-3 cells treated with Nexrutine (5 mg/ml) for different
periods. As shown in Figure 4B, there was no significant
change in the levels of total Akt. However, levels of pAkt were
undetectable from 24-hour treated extract. Similar results
were obtained in LNCaP cells (data not shown). We also
monitored the phosphorylation of Akt using FACE kit that
specifically measures activated Akt and/or total Akt quanti-
tatively (Active Motif). As shown in Figure 4C, the levels of
Figure 4. Nexrutine treatment reduces the expression of pAkt. (A) Cells treated with Nexrutine (5 g/ml for 24 hours) were fixed on slides using paraformaldehyde.
Fixed slides were blocked in horse serum as described in Materials and Methods and incubated with the selected primary antibody (pAkt), diluted in blocking buffer
(based on the manufacturer’s recommendations) overnight at 4jC with gentle rocking. After three washes with TBS/Triton, the slides were incubated with a
Universal Secondary antibody for 1 hour at room temperature. After washes with TBS and TBS/Triton, the slides were incubated with 0.6% hydrogen peroxide for
30 minutes. The slides were washed once more with TBS and TBS/Triton and stable DAB was added to each spot on the slide for 15 to 20 minutes. Slides were
then rinsed with water and mounted with a coverslip. (B) Logarithmically growing PC-3 cells were treated with 5 g/ml Nexrutine or with solvent control for different
periods (0, 3, 6, 12, and 24 hours) and whole-cell extracts were prepared. Western blotting was performed as described above for Figure 3C. The blot shown is a
representative blot that was repeated three different times. (C) To measure levels of total and phosphorylated Akt using FACE-Akt kit, exponentially growing cells in
96-well plates were treated with different concentrations of Nexrutine. Cells were rapidly fixed and incubated with a primary antibody that recognizes either
phosphorylated or total Akt. This was followed by incubation with secondary HRP-conjugated antibody followed by colorimetric development. Relative number of
cells in each well was determined using crystal violet reagent for normalizing the data. The data shown here is a representative of three experiments and the values
represent averages obtained from triplicate wells. (D) Subconfluent LNCaP cells were transfected with either pCMVMyrAkt (an activated form of Akt with the Src
myristoylation signal fused in-frame to the c-Akt coding sequence) or control vector (pCMV) using Lipofectamin (Invitrogen) in triplicate dishes. Forty-eight hours
after transfection, cells were treated with either 5 g/ml Nexrutine or solvent control. Both floating and adherent cells were collected after 24 hours of treatment and
assessed for cell viability by trypan blue exclusion assay. Data are averages ± S.D. of three independent experiments.
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phosphorylated Akt decreased, whereas the levels of total
Akt did not change significantly, which is consistent with the
Western blot data presented above. To show the direct in-
volvement of Akt inactivation in Nexrutine-induced growth
inhibition and apoptosis, we measured cell viability and
apoptosis in LNCaP cells ectopically expressing constitu-
tively active myristoylated Akt (transfected either with
pCMVMyrAkt, which bypasses the requirement for pleckstrin
homology domain–mediated membrane recruitment, or with
control vector, pCMV) as described earlier [16]. As shown in
Figure 4D, Nexrutine treatment inhibited the growth of
LNCaP cells transfected with control vector and is consistent
with the above cell proliferation data. In contrast, overex-
pression of constitutively active Akt protected LNCaP cells
from growth-inhibitory activity of Nexrutine. Microscopic ob-
servations of vector-transfected cells show characteristic
features of apoptosis unlike MyrAkt-transfected cells after
treatment with Nexrutine (data not shown). These results
demonstrate that inhibition of Akt activation is an important
signaling event induced by Nexrutine in these cells. How-
ever, it is not known whether Akt inactivation is the pri-
mary cause or the observed effects are a consequence of
Akt inactivation.
Our results are consistent with published data showing
induction of apoptosis in PCA cells by blocking Akt activation
independent of Bcl-2 by celecoxib, a Cox-2 inhibitor [34]. Be-
cause one of the downstream targets of Akt is CREB, we
determined the levels of total CREB and phosphorylated
CREB (pCREB) in nuclear extracts from LNCaP cells after
treatment with Nexrutine (0, 1, 2.5 and 5 mg/ml) for 24 hours
using Western blot analysis. As shown in Figure 5A, after
treatment with Nexrutine the level of pCREB was reduced
Figure 5. Nexrutine treatment reduces the levels of pCREB and CREB DNA-binding activity in LNCaP and PC-3 cells. Logarithmically growing LNCaP cells were
treated with Nexrutine (0, 1, 2.5, and 5 g/ml for 24 hours) or with solvent control and nuclear extracts were prepared. In the case of PC-3 cells, cells were treated
with 5 g/ml of Nexrutine for different periods (0, 3, 6, 12, and 24 hours). Western blotting was performed as described for Figure 4B. (A) Western blotting of LNCaP
extracts. (B) Western blotting of extracts prepared from PC-3 cells. Nuclear extracts prepared from human fibroblast WI-38 cells stimulated with forskolin (CREB
activator) was used as positive control (Std). (C) CREB DNA-binding activity was measured in LNCaP nuclear extracts by using TransAM CREB (Active Motif).
Briefly, the control and Nexrutine-treated nuclear extracts were incubated with CREB consensus oligonucleotide that was immobilized in 96-well plates. A primary
antibody specific for an epitope on the bound and active form of the CREB was then added followed by subsequent incubation with secondary antibody and
developing solution. After this incubation with the developing solution, CREB activity was measured colorimetrically at 450 nm. Nuclear extracts prepared from
human fibroblast WI-38 cells stimulated with forskolin (CREB activator) were used as positive control. For competition experiments, the wells containing
immobilized oligo were preincubated with 100-fold molar excess of wild-type and mutant oligonucleotide for 30 min before addition of the nuclear extract. (D) CREB
DNA-binding activity in PC-3 cells using TransAM CREB (Active Motif) as described above for (C). (E) Akt kinase activity in extracts prepared from PC-3 cells
treated with Nexrutine (5 g/ml) for different time intervals. Endogenous Akt was immunoprecipitated with Akt antibody. Kinase reaction was performed in the
presence of cold ATP and GSK-3 substrate as per manufacturer’s recommendations (Cell Signaling Technology). Phosphorylation of GSK-3 was measured by
Western blotting using an anti –phosphoGSK-3 antibody. The blot shown is a representative blot of two independent experiments.
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with no significant changes in the levels of total CREB. Nu-
clear extracts were prepared from PC-3 cells treated with
5 mg/ml of Nexrutine for 0, 3, 6, 12, and 24 hours. As shown in
Figure 5B, CREB antibody detected a doublet band repre-
senting phosphorylated (indicated by an arrow) and unphos-
phorylated forms. However, the intensity of phosphorylated
form was reduced in extracts prepared from cells treated with
Nexrutine. We confirmed these observations using phospho-
specific CREB antibody (Figure 5B). The identity of the bands
in Figure 5B are pCREB (46 kDa); phosphorylated CREM
(30 kDa), and ATF-1 (38 kDa). Forskolin-treated WI-38 cell
extract was used as positive control. These data suggest
that Nexrutine treatment reduces the levels of the phosphory-
lated form of CREB in LNCaPandPC-3 cells. BecauseCREB
has been shown to regulate the expression of genes involved
in various cellular processes including Bcl-2, we measured
CREB DNA-binding activity in nuclear extracts prepared
from LNCaP and PC-3 cells. As shown in Figure 5C, nuclear
extracts prepared fromuntreated LNCaP cells showedCREB
DNA-binding activity that was reduced with Nexrutine treat-
ment. Use of 100-fold molar excess of cold competitor (wild-
type CREB consensus oligo sequence) inhibited the CREB
DNA binding but not the mutant CREB consensus oligo
sequence, indicating that the observed DNA binding is se-
quence specific. Experiments using nuclear extracts pre-
pared from PC-3 cells treated with Nexrutine for different
time points are shown in Figure 5D. CREB DNA-binding
activity showed a statistically significant reduction in a time-
dependent manner (P < .01 at 12-hour time point). We also
investigated if Nexrutine-mediated biologic effects involve
modulation of Akt kinase activity. As shown in Figure 5E, ex-
tracts prepared from untreated PC-3 cells showed Akt kinase
activity. However, treatment with Nexrutine (5 mg/ml) led to
undetectable levels of Akt kinase activity within 3 hours.
These data indicate constitutive levels of Akt kinase activity
protect PC-3 cells from undergoing apoptosis and that
treatment with Nexrutine induces apoptosis possibly by in-
hibiting Akt kinase activity. It is also noteworthy to mention
that CREB has been shown to be a substrate for various
kinases including Akt [33]. Our findings showing reduction
in the levels of pCREB and reduced CREB DNA-binding
activity in Nexrutine-treated extracts implicate a potential
role for Akt/CREB signaling in mediating Nexrutine-induced
biologic response.
Discussion
Although evidence from epidemiological and animal studies
suggests that increased consumption of plant-based diet
can reduce the risk of PCA, presently, little information is avail-
able concerning the use of botanicals in preventing PCA. As a
first step toward developing botanicals as PCA preventives,
we examined the effect of Nexrutine on human PCA cell lines.
Overall, our results suggest that Nexrutine inhibits tumor
cell proliferation by a combination of apoptosis induction
and inhibition of cell survival signaling. The results of the
present study demonstrate that Nexrutine treatment 1) in-
hibits the proliferation of human PCA cells through induction of
apoptosis independent of Bcl-2; 2) results in reduction in the
levels of pAkt, and overexpression of Akt protects cells from
Nexrutine-induced inhibition of cell proliferation implicating
a role for Akt signaling; and 3) reduces the levels of pCREB
and CREB DNA-binding activity. Because overexpression
of Bcl-2 is associated with advance hormone-refractory pros-
tate tumors, the observed induction of apoptosis in response
to Nexrutine in the presence of Bcl-2 is novel. This also in-
dicates a potential for this agent not only in the treatment
of metastatic PCA, but also in the therapy of neoplasms other
than prostate that overexpress Bcl-2.
The significant outcome of this study is the finding that
enforced activation of Akt largely blocked Nexrutine-induced
inhibition of cell proliferation and the induction of apoptosis.
These implicate a direct role for Akt signaling in PCA growth
inhibition in response to Nexrutine. This observation also
raises the possibility that this agent might prove useful in neo-
plasms characterized by PTEN mutations in which inappro-
priate Akt activation plays a role in enhanced survival [29].
We also observed a correlation between Nexrutine-induced
apoptosis and levels of pCREB and CREB DNA-binding
activity. Because Akt has been shown to phosphorylate
CREB, it is possible that Akt-mediated activation of CREB
plays an important role in prostate carcinogenesis [33].
The transcription factor CREB regulates genes involved in
various cellular processes by binding to cAMP response
element (CRE) sequences present in their promoter regions
[35,36]. A number of growth factors, hormones, and a variety
of protein kinases including protein kinase A (PKA), mitogen-
activated PKs (MAPKs), Ca2+/calmodulin-dependent PKs
(CaMKs), and Akt have been shown to activate CREB
[35,36]. Transgenic mice overexpressing dominant-negative
CREB induces apoptosis in T cells after growth factor stimu-
lation, implicating CREB as an important factor for cell
survival [37]. More importantly, it has been shown that inter-
actions between CREB and androgen receptor (AR) signal-
ing pathways may be one of the contributing factors involved
in the development of androgen-independent PCA [38]. The
widely used serummarker for PCA, namely, prostate-specific
antigen gene, contains a putative binding site for CREB lo-
cated at 3196/3189 [38]. Recently, it has been demon-
strated that interactions between AR and CREB through
coactivator proteins including CBP/p300 regulate prostate-
specific antigen gene expression. Thus, it is reasonable to
speculate that Nexrutine may exert its growth inhibitory ef-
fects by disruption of AR/CREB interactions directly or
through reduction in the levels of coactivator protein CBP/
p300 or other unidentified proteins. Nonetheless, disruption
of Akt signaling by Nexrutine may also reduce the levels
of pCREB because Akt has been shown to phosphorylate
CREB. However, it is not known if Nexrutine acts upstream
of Akt at the level of PI3K signaling, and such studies are cur-
rently in progress. The role of the other Akt downstream sig-
naling pathways including NFnB, FKHR, etc. is not ruled out.
The results of this study could have implications for
incorporation of herbal extracts such as Nexrutine into the
prevention/therapeutic strategies against PCA and other
cancers. An added advantage of Nexrutine is that it is
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safe to consume and biologically active in human test sub-
jects. A contract research company (Dennis and Company
Research, Stanford, CT) conducted an open-label, home-
use trial on Nexrutine. Fifty-three dietary supplement users
who suffered from joint or muscle pain took one or two
Nexrutine capsules once or twice daily for 2 weeks. The
study included 29 men and 24 women (La Valle, 2006,
personal communication). The average age of the subjects
was 49 years. Seven of 10 subjects rated the product as
effective, reporting that their muscles were less sore after
physical activities. Nine of 10 felt Nexrutine was gentle on
the stomach and reported minimal side effects. Our data
show that Nexrutine induces apoptosis involving multiple
mechanisms in part by blocking the activation of an anti-
apoptotic kinase Akt and transcription factor CREB in a Bcl-
2–independent fashion. More importantly, inhibition of these
multiple signaling pathways with Nexrutine resulted in re-
duction in the colony-forming efficiency in a soft agar assay
indicating that inhibition of this pathway plays an important
role in oncogenecity in these cells. Based on our results, we
speculated that Akt-mediated activation of CREB may play
an important role in the PCA progression and that Nexrutine
blocks this pathway. We cannot rule out the possibility that
MAPKs such as ERK and p38 may also act as upstream
regulators in the activation of CREB. Nevertheless, our find-
ings indicate that this pathway plays a role in the progression
of PCA and that control of this pathway may have a potential
in the prevention of PCA. Furthermore, the nature of the bio-
logically active component in this extract is not known. Ad-
ditional studies, including preclinical studies, to identify the
biologically active principle and the precise molecular path-
ways regulating apoptotic response to this agent are cur-
rently in progress in the laboratory.
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